Improvement in vision: A new goal for treatment of hereditary retinal degenerations

Expert Opinion on Orphan Drugs

Volumn 3, Issue 5, 2015, Pages 563-575

  Jacobson, Samuel G ^a   Cideciyan, Artur V ^a   Aguirre, Gustavo D ^b   Roman, Alejandro J ^a   Sumaroka, Alexander ^a   Hauswirth, William W ^c   Palczewski, Krzysztof ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF VETERINARY MEDICINE   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene therapy; Leber congenital amaurosis; Photoreceptors; Retina; Retinal pigment epithelium; Retinoid cycle

Indexed keywords

9 CIS RETINOID; PROTEIN; RETINAL PIGMENT EPITHELIUM SPECIFIC PROTEIN 65 KDA; RETINOID; RETINOID DERIVATIVE; UNCLASSIFIED DRUG;

ADENO ASSOCIATED VIRUS; ADVERSE OUTCOME; BLINDNESS; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GENE AUGMENTATION THERAPY; GENE MUTATION; GENE THERAPY; GENE VECTOR; HUMAN; IN VIVO STUDY; INHERITED RETINAL DEGENERATION; INTERMETHOD COMPARISON; LEBER CONGENITAL AMAUROSIS; LONG TERM CARE; MOLECULARLY TARGETED THERAPY; NONHUMAN; NONVIRAL GENE THERAPY; OPTICAL TOMOGRAPHY; PRIORITY JOURNAL; RETINA; RETINA CONE; RETINA DEGENERATION; RETINA FOVEA; RETINAL NERVE FIBER LAYER THICKNESS; REVIEW; SUBRETINAL SPACE; VISION;

EID: 84928616941     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2015.1030393     Document Type: Review

References (80)

1. Bramall AN, Wright AF, Jacobson SG, McInnes RR. The genomic, biochemical, and cellular responses of the retina in inherited photoreceptor degenerations and prospects for the treatment of these disorders. Annu Rev Neurosci 2010;33:441-72
2. Wright AF, Chakarova CF, Abd El-Aziz MM, Bhattacharya SS. Photoreceptor degeneration: genetic and mechanistic dissection of a complex trait. Nat Rev Genet 2010;11:273-84
3. Hamel CP. Gene discovery and prevalence in inherited retinal dystrophies. C R Biol 2014;337:160-6
4. Berson EL. Nutrition and retinal degenerations. Int Ophthalmol Clin 2000;40:93-111
5. Hoffman DR, Locke KG, Wheaton DH, et al. A randomized, placebo-controlled clinical trial of docosahexaenoic acid supplementation for X-linked retinitis pigmentosa. Am J Ophthalmol 2004;137:704-18
6. RetNet: retinal Information Network. Daiger SP and the University of Texas Health Science Center. RetNet, Houston, TX; 2014. Available from: https://sph.uth.edu/retnet/ [Last accessed 10 December 2014]
7. Cideciyan AV. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res 2010;29:398-427
8. Colella P, Auricchio A. Gene therapy of inherited retinopathies: a long and successful road from viral vectors to patients. Hum Gen Ther 2012;23:796-807
9. Hufnagel RB, Ahmed ZM, Correa ZM, Sisk RA. Gene therapy for Leber congenital amaurosis: advances and future directions. Graefes Arch Clin Exp Ophthalmol 2012;250:1117-28
10. Boye SE, Boye SL, Lewin AS, Hauswirth WW. A comprehensive review of retinal gene therapy. Mol Ther 2013;3:509-19
11. Carvalho LS, Vandenberghe LH. Promising and delivering gene therapies for vision loss. Vision Res 2014;doi: 10.1016/j.visres.2014.07.013
12. Pierce EA, Bennett J. The status of RPE65 gene therapy trials: safety and efficacy. CSH Perspect Med 2015;doi: 10.1101/cshperspect. a017285
13. Thompson DA, Ali RR, Banin E, et al. Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano symposium. Invest Ophthalmol Vis Sci 2015;56:918-31
14. Saari JC. Biochemistry of visual pigment regeneration: the Friedenwald lecture. Invest Ophthalmol Vis Sci 2000;41:337-48
15. Travis GH, Golczak M, Moise R, Palczewski K. Diseases caused by defects in the visual cycle: retinoids as potential therapeutic agents. Annu Rev Pharmacol Toxicol 2007;47:469-512
16. Palczewski K. Retinoids for treatment of retinal diseases. Trends Pharmacol Sci 2010;31:289-95
17. Tang PH, Kono M, Koutalos Y, et al. New insights into retinoid metabolism and cycling within the retina. Prog Retin Eye Res 2013;23:48-63
18. Palczewski K. Chemistry and biology of the initial steps in vision: the Friedenwald Lecture. Invest Ophthalmol Vis Sci 2014;55:6651-72
19. Jacobson SG, Aleman TS, Cideciyan AV, et al. Identifying photoreceptors in blind eyes caused by RPE65 mutations: prerequisite for human gene therapy success. Proc Natl Acad Sci USA 2005;102:6177-82
20. Jacobson SG, Aleman TS, Cideciyan AV, et al. Human cone photoreceptor dependence on RPE65 isomerase. Proc Natl Acad Sci USA 2007;104:15123-8
21. Jacobson SG, Cideciyan AV, Aleman TS, et al. Photoreceptor layer topography in children with Leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci 2008;49:4573-7
22. Jacobson SG, Aleman TS, Cideciyan AV, et al. Defining the residual vision in Leber congenital amaurosis caused by RPE65 mutations. Invest Ophthalmol Vis Sci 2009;50:2368-75
23. Mata NL, Radu RA, Clemmons RC, Travis GH. Isomerization and oxidation of vitamin a in cone-dominant retinas: a novel pathway for visual-pigment regeneration in daylight. Neuron 2002;36:69-80
24. Kaylor JJ, Yuan Q, Cook J, et al. Identification of DES1 as a vitamin A isomerase in Muller glial cells of the retina. Nat Chem Biol 2013;9:30-6
25. Xue Y, Shen SQ, Jui J, et al. CRALBP supports the mammalian retinal visual cycle and cone vision. J Clin Invest 2015;125:727-38
26. Van Hooser JP, Aleman TS, He YG, et al. Rapid restoration of visual pigment and function with oral retinoid in a mouse model of childhood blindness. Proc Natl Acad Sci USA 2000;97:8623-8
27. Van Hooser JP, Liang Y, Maeda T, et al. Recovery of visual functions in a mouse model of Leber congenital amaurosis. J Biol Chem 2002;277:19173-82
28. Ablonczy Z, Crouch RK, Goletz PW, et al. 11-cis-retinal reduces constitutive opsin phosphorylation and improves quantum catch in retinoid-deficient mouse rod photoreceptors. J Biol Chem 2002;277:40491-8
29. Maeda T, Maeda A, Casadesus G, et al. Evaluation of 9-cis-retinyl acetate therapy in Rpe65-/- mice. Invest Ophthalmol Vis Sci 2009;50:4368-78
30. Maeda T, Cideciyan AV, Maeda A, et al. Loss of cone photoreceptors caused by chromophore depletion is partially prevented by the artificial chromophore pro-drug, 9-cis-retinyl acetate. Hum Mol Genet 2009;18: 2277-87
31. Gearhart PM, Gearhart C, Thompson DA, Petersen-Jones SM. Improvement of visual performance with intravitreal administration of 9-cis-retinal in Rpe65-mutant dogs. Arch Ophthalmol 2010;128:1442-8
32. Maeda A, Palczewski K. Retinal degeneration in animal models with a defective visual cycle. Drug Discov Tod Dis Models 2013;10:e163-72
33. Imanishi Y, Batten ML, Piston DW, et al. Noninvasive two-photon imaging reveals retinyl ester storage structures in the eye. J Cell Biol 2004;164:373-83
34. Orban T, Palczewska G, Palczewski K. Retinyl ester storage particles (retinosomes) from the retinal pigmented epithelium resemble lipid droplets in other tissues. J Biol Chem 2011;283:17248-58
35. Hubbard R, Wald G. Cis-trans isomers of vitamin A and retinene in the rhodopsin system. J Gen Physiol 1952;36:269-315
36. Fan J, Rohrer B, Moiseyev G, et al. Isorhodopsin rather than rhodopsin mediates rod function in RPE65 knockout mice. Proc Natl Acad Sci USA 2003;100:13662-7
37. Palczewski K. G protein-coupled receptor rhodopsin. Annu Rev Biochem 2006;75:743-67
38. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001;28:92-5
39. Acland GM, Aguirre GD, Bennett J, et al. Long-term restoration of rod and cone vision by single dose rAAVmediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 2005;12:1072-82
40. Aguirre GK, Komáromy AM, Cideciyan AV, et al. Canine and human visual cortex intact and responsive despite early retinal blindness from RPE65 mutation. PLoS Med 2007;4:e230
41. Caruso RC, Aleman TS, Cideciyan AV, et al. Retinal disease in Rpe65-deficient mice: comparison to human Leber congenital amaurosis due to RPE65 mutations. Invest Ophthalmol Vis Sci 2010;51:5304-13
42. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci USA 2013;110:E517-25
43. Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber?s congenital amaurosis. N Engl J Med 2008;358:2231-9
44. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber?s congenital amaurosis. N Engl J Med 2008;358:2240-8
45. Hauswirth WW, Aleman TS, Kaushal S, et al. Treatment of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adenoassociated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 2008;19:979-90
46. Cideciyan AV, Aleman TS, Boye SL, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci USA 2008;105:15112-17
47. Banin E, Bandah-Rozenfeld D, Obolensky A, et al. Molecular anthropology meets genetic medicine to treat blindness in the North African Jewish population: human gene therapy initiated in Israel. Hum Gene Ther 2010;21:1749-57
48. Jacobson SG, Cideciyan AV, Ratnakaram R. Gene therapy for Leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol 2012;130:9-24
49. Cideciyan AV, Hauswirth WW, Aleman TS, et al. Vision 1 year after gene therapy for Leber?s congenital amaurosis. N Engl J Med 2009;361:725-7
50. Cideciyan AV, Aguirre GK, Jacobson SG, et al. Pseudo-fovea formation after gene therapy for RPE65-LCA. Invest Ophthalmol Vis Sci 2014;56:526-37
51. Koenekoop RK, Rufang S, Sallum J, et al. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial. Lancet 2014;384:1513-20
52. Cideciyan AV, Moore AT, Zrenner E, et al. Increased vision within days of oral cis-retinoid (QLT091001) treatment in blindness due to mutations in retinal pigment epithelium-specific protein 65kDa (RPE65) or lecithin retinol acyltransferase (LRAT). ARVO Meeting Abstract 2012;53:6965
53. Redmond TM, Poliakov E, Yu S, et al. Mutation of key residues of Rpe65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci USA 2005;102:13658-63
54. Philp AR, Jin M, Li S, et al. Predicting the pathogenicity of RPE65 mutations. Hum Mutat 2009;30:1183-8
55. Li S, Izumi T, Hu J, et al. Rescue of enzymatic function for disease-associated RPE65 proteins containing various missense mutations in non-active sites. J Biol Chem 2014;289:18943-56
56. Roman AJ, Schwartz SB, Aleman TS, et al. Quantifying rod photoreceptormediated vision in retinal degenerations: dark-adapted thresholds as outcome measures. Exp Eye Res 2005;80:259-72
57. Roman AJ, Cideciyan AV, Aleman TS, et al. Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials. Physiol Meas 2007;25:N51-6
58. Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010;116:544-73
59. Blagosklonny MV. NCI?s provocative questions on cancer: some answers to ignite discussion. Oncotarget 2011;2:1352-67
60. Bennett J, Ashtari M, Wellman J, et al. AAV2 gene therapy readministration in three adults with congenital blindness. Sci Transl Med 2012;4:120ra15
61. Han Z, Conley SM, Makkia R, et al. Comparative analysis of DNA nanoparticles and AAVs for ocular gene delivery. PLoS One 2012;7:e52189
62. Koirala A, Makkia RS, Conley SM, et al. S/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA. Hum Mol Genet 2013;22:1632-42
63. Koirala A, Conley SM, Makkia R, et al. Persistence of non-viral vector mediated RPE65 expression: case for viability as a gene transfer therapy for RPE-based diseases. J Control Release 2013;172:745-52
64. Jacobson SG, Cideciyan AV. Treatment possibilities for retinitis pigmentosa. N Eng J Med 2010;363:1669-71
65. Chader GJ, Weiland J, Humayun MS. Artificial vision: needs, functioning, and testing of a retinal electronic prosthesis. Prog Brain Res 2009;175:317-32
66. Weiland JD, Cho AK, Humayun MS. Retinal prostheses: current clinical results and future needs. Ophthalmology 2011;118:2227-37
67. Rizzo JF III, Shire DB, Kelly SK, et al. Overview of the boston retinal prosthesis: challenges and opportunities to restore useful vision to the blind. Cong Proc IEEE Eng Med Biol Soc 2011;2011:7492-5
68. Garg SJ, Federman J. Optogenetics, visual prosthesis and electrostimulation for retinal dystrophies. Curr Opin Ophthalmol 2013;24:407-14
69. Picaud S, Sahel J-A. Retinal prostheses: clinical results and future challenges. C R Biol 2014;337:214-22
70. Fenno L, Yizhar O, Deisseroth K. The development and application of optogenetics. Annu Rev Neurosci 2011;34:389-412
71. Nirenberg S, Pandarinath C. Retinal prosthetic strategy with the capacity to restore normal vision. Proc Natl Acad Sci USA 2012;109:15012-17
72. Jacobson SG, Sumaroka A, Luo K, Cideciyan AV. Retinal optogenetic therapies: clinical criteria for candidacy. Clin Genet 2013;84:175-82
73. Gaub BM, Berry MH, Holt AE, et al. Restoration of visual function by expression of a light-gated mammalian ion channel in retinal ganglion cells or ON-bipolar cells. Proc Natl Acad Sci USA 2014;111(51):E5574-83
74. Schwartz SD, Regillo CD, Lam BL, et al. Human embryonic stem cellderived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt?s macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 2015;385(9967):509-16
75. Wiley LA, Burnight ER, Songstad AE, et al. Patient-specific induced pluripotent stem cells (iPSCs) for the study and treatment of retinal degenerative diseases. Prog Retin Eye Res 2015;44:15-35
76. Porter LF, Black GCM. Personalized ophthalmology. Clin Genet 2014;86:1-11
77. Meyer UA. Personalized medicine: a personal view. Clin Pharmacol Ther 2012;91:373-5
78. Stone EM. Finding and interpreting genetic variations that are important to ophthalmologists. Trans Am Ophthalmol Soc 2003;101:437-84
79. Brooks BP, Macdonald IM, Tumminia SJ, et al. National Ophthalmic Disease Genotyping Network (eyeGENE). Genomics in the era of molecular ophthalmology: reflections on the National Ophthalmic Disease Genotyping Network (eyeGENE). Arch Ophthalmol 2008;126:424-5
80. Zeitz C, Robson AG, Audo I. Congenital stationary night blindness: An analysis and update of genotype-phenotype correlations and pathogenic mechanisms. Prog Retin Eye Res 2015;45C:58-110